TRIUMPH-1: Retatrutide Posts Bariatric-Level Weight Loss in Phase 3
Published: May 22, 2026 · 4 min read · By Grey Peptides News Desk · ✓ Sourced
On May 21, 2026, Eli Lilly reported topline results from TRIUMPH-1, the first pivotal Phase 3 obesity trial of retatrutide — its once-weekly GIP, GLP-1, and glucagon triple receptor agonist. In 2,339 adults with obesity or overweight (without type 2 diabetes), the 12 mg dose produced a mean weight loss of 28.3% at 80 weeks, and a subgroup followed to 104 weeks reached 30.3%. These are the largest weight-loss figures any obesity drug has reported in a Phase 3 trial. Retatrutide is still investigational and not FDA-approved.
The numbers, and why they matter
TRIUMPH-1 tested three doses against placebo. At 80 weeks, participants on 12 mg lost an average of 28.3% of body weight (about 70 lbs), those on 9 mg roughly 23.7%, and those on 4 mg about 17.6% — versus 3.9% on placebo. Nearly half (45.3%) of the top-dose group lost 30% or more of their body weight, a threshold historically associated with bariatric surgery rather than pharmacology. In a pre-specified extension, higher-BMI participants who continued to 104 weeks reached up to 30.3%.
For context: the highest approved doses of tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy) have each landed around 20–21% in their pivotal trials. Retatrutide's added glucagon-receptor activity — the "third agonist" — appears to push the ceiling several points higher. That is the entire thesis behind triple agonism, and TRIUMPH-1 is the cleanest confirmation of it so far.
Where we'd add caution
Topline press releases are not peer-reviewed data, and the most interesting questions live in the detail that hasn't been published yet. Two are worth holding in mind.
Tolerability and discontinuation. The earlier TRIUMPH-4 readout (obesity with knee osteoarthritis) flagged dysesthesia — an abnormal skin-sensation side effect — and adverse-event discontinuation rates that climbed with dose. Whether TRIUMPH-1 shows a cleaner profile, and how much of the dropout was driven by patients losing more weight than they wanted, matters for how this drug would actually be used.
Body composition. Weight loss of this magnitude inevitably raises the lean-mass question. As with every high-efficacy incretin, the figure that matters clinically is how much of the loss is fat versus muscle — and that DXA breakdown wasn't in the topline.
What happens next
Lilly says detailed TRIUMPH-1 data will be presented at the American Diabetes Association 2026 Scientific Sessions (June 5–8, New Orleans), with the type 2 diabetes trial (TRANSCEND-T2D-1) alongside it. Several more Phase 3 readouts across the TRIUMPH program — cardiovascular disease, sleep apnea, maintenance dosing — are expected through the rest of the year before any regulatory filing. Retatrutide is not approved, is not available by prescription, and the research-grade material circulating online is not FDA-reviewed for human use.
The short version: the efficacy ceiling for obesity pharmacotherapy just moved again, and it moved a lot. The open questions are now about safety and durability, not whether the mechanism works.
Related on Grey Peptides
Triple-agonist mechanism, full trial history, and current regulatory status. Retatrutide vs Tirzepatide
How the triple agonist compares with the approved dual agonist on efficacy and mechanism. Best Peptides for Fat Loss (2026)
Where retatrutide sits among the current and pipeline weight-loss options.
Eli Lilly — Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial ↗
Topline release: May 21, 2026. TRIUMPH-1 (NCT05929066). Detailed data to be presented at ADA 2026 Scientific Sessions, June 5–8, New Orleans.